According to William Walker, Ph.D., Oncology Med's CEO and founder, "As I have previously stated, these new contracts are additional client sites of the many that we hope to announce to our investors and other interested parties over the next several quarters centered around one of our new turnkey programs for cancer treatment."
Jack Sloan, Vice President of Business Development, added, "We consider our company to be unique in the market as opposed to other turnkey cancer providers who are management companies who sub-contract out the necessary professional and technical pieces of their programs to subcontractors for the requisite components to provide a full turnkey program. As a result of this structure they have to charge higher fees to the client to cover the management cost. Oncology Med is a full-service clinical company to which many management companies have turned in the past to fulfill their obligations in providing turnkey cancer solutions. Therefore, Oncology Med can enter the competitive arena of turnkey cancer solutions with all services under one roof, provide faster installation of new programs, equipment, services, and staff, and do so at a lower cost to the client than our competitors."
Oncology Med's new approach to the market allows it more control of its profits and future by securing additional multi-year contracts directly with large and small medical systems, ambulatory surgery centers, and cancer institutes rather than rely on 'per click' usage of its services by management companies with no long term contractual commitment to Oncology Med and its programs and services.
"We will still contract and seek out relationships with key cancer management companies and other medical facility groups; however, we will expect more long-term commitment from the management companies we choose to contract with and align our resources going forward for a more equitable and financially beneficial contractual relationship for both companies," continued Sloan.
"With the changes in reimbursement from the Center for Medicare and Medicare Services (CMS) which were instituted in January of 2008 for prostate brachytherapy services in the ambulatory surgery centers (ASCs) and the exemption given to physician-owned ASCs, we have seen a marked increase in the interest shown by many centers across the country to add prostate cancer brachytherapy to their list of offered procedures," Walker contended.
"Under the new reimbursement guidelines established by CMS, prostate cancer brachytherapy is an excellent additional revenue stream for most ambulatory surgery centers where the ASC either has urology participation or chooses to add urology services and are seeking additional value for its investors and shareholders," Sloan stated.
Oncology Med's depth of staff, expertise, and technological advanced planning systems and equipment positions the company to be sought out by ambulatory surgery centers, hospitals, medical systems, and cancer centers who seek to expand and/or improve services without the burden and cost of bringing on additional internal staff that are not fully necessary or which lack the experience and expertise of those provided through Oncology Med.
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of services related to the treatment of various cancers. It currently provides analysis and design of radiation treatment plans in order for radiation oncologists to administer radiation treatments to cancer patients. Current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.
More information about Oncology Med, Inc. can be found at www.oncologymed.com.
NOTE: This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results.
For information, please contact: William Walker, Ph.D. Oncology Med, Inc. 1-504-822-5161
SOURCE: Oncology Med, Inc.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
|
|
